• 1. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 2. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 3. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 4. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 5. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569

Professional Introduction to 4-Phenoxy-1H-indazol-3-ylamine (CAS No. 816454-31-6)

4-Phenoxy-1H-indazol-3-ylamine, identified by its Chemical Abstracts Service (CAS) number 816454-31-6, is a significant compound in the realm of pharmaceutical chemistry. This heterocyclic amine derivative has garnered attention due to its structural complexity and potential biological activities. The compound belongs to the indazole family, which is well-documented for its role in various pharmacological applications.

The molecular structure of 4-phenoxy-1H-indazol-3-ylamine consists of a phenoxy group attached to an indazole core, which is further substituted with an amine functional group at the 3-position. This particular arrangement of functional groups makes it a versatile scaffold for medicinal chemists, enabling modifications that can fine-tune its pharmacokinetic and pharmacodynamic properties.

In recent years, there has been a surge in research focused on indazole derivatives due to their demonstrated efficacy in modulating various biological pathways. The presence of the phenoxy group in 4-phenoxy-1H-indazol-3-ylamine introduces hydrophobicity and potential interactions with specific binding sites, enhancing its bioavailability and target specificity. These characteristics make it a promising candidate for further exploration in drug discovery.

One of the most compelling aspects of 4-phenoxy-1H-indazol-3-ylamine is its potential application in the treatment of neurological disorders. Studies have indicated that indazole derivatives can interact with neurotransmitter receptors, potentially offering therapeutic benefits in conditions such as depression, anxiety, and neurodegenerative diseases. The amine group in this compound allows for further derivatization, enabling the development of more potent and selective analogs.

The synthesis of 4-phenoxy-1H-indazol-3-ylamine involves multi-step organic reactions, typically starting from commercially available precursors. The process requires careful optimization to ensure high yield and purity. Advanced synthetic techniques, such as palladium-catalyzed cross-coupling reactions, have been employed to achieve the desired substitution pattern on the indazole core. These methods not only enhance efficiency but also minimize unwanted byproducts.

Evaluation of the pharmacological properties of 4-phenoxy-1H-indazol-3-ylamine has revealed several intriguing findings. In vitro studies have demonstrated its ability to inhibit certain enzymes and receptors relevant to inflammation and pain modulation. Additionally, preliminary in vivo experiments suggest that it may exhibit anxiolytic and antidepressant effects, although further research is needed to confirm these observations.

The potential therapeutic applications of this compound extend beyond neurological disorders. Research is ongoing to explore its efficacy in other areas, such as cancer chemoprevention and anti-inflammatory therapies. The phenoxy group's ability to modulate signaling pathways associated with cell proliferation and apoptosis makes it a valuable candidate for these investigations.

The development of novel pharmaceutical agents often involves a rigorous evaluation process to assess safety and efficacy. For 4-phenoxy-1H-indazol-3-ylamine, this includes toxicological studies to determine its metabolic stability and potential side effects. Advanced computational modeling techniques are also employed to predict how the compound will interact with biological targets, providing insights into its mechanism of action.

The role of computational chemistry in drug discovery cannot be overstated. Molecular docking simulations have been particularly useful in understanding how 4-phenoxy-1H-indazol-3-ylamine interacts with proteins such as kinases and transcription factors. These interactions are critical for designing molecules that can modulate disease-related pathways effectively.

In conclusion, 4-phenoxy-1H-indazol-3-ylamine (CAS No. 816454-31-6) represents a promising compound with significant potential in pharmaceutical applications. Its unique structural features and demonstrated biological activities make it a valuable asset in the search for new therapeutics. As research continues to uncover more about its properties and mechanisms of action, this compound is poised to play a crucial role in addressing various health challenges.

• 58514-96-8(5-methoxy-1H-indazol-3-amine)
• 88805-68-9(3-Amino-1H-indazol-4-ol)
• 886362-07-8(4-methoxy-1H-indazol-3-amine)
• 88805-72-5(3-Amino-6-hydroxy-1H-indazole)
• 62732-90-5(1H-Indazol-3-amine, 5,6-dimethoxy-, monohydrochloride)
• 62732-89-2(1H-Indazol-3-amine, 5,6-dimethoxy-)
• 1158765-05-9(N'-[(e)-(2-bromophenyl)methylene]-2-[4-(4-chlorobenzyl)-1-piperaz Inyl]acetohydrazide)
• 1000018-07-4(1-Methyl-4-phenoxy-1H-indazol-3-amine)
• 511225-17-5(6-Methoxy-1H-indazol-3-amine)
• 1000341-20-7(4-Amino-6-methoxy 1H-Indazole)